ACAna Caratozzolo

Ana Caratozzolo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Caratozzolo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Eduardo Luis Lopez

    Department of Medicine, Pediatric Infectious Diseases Program, Hospital de Niños Dr. Ricardo Gutiérrez, Universidad de Buenos Aires, Buenos Aires, Argentina

    2 shared publications
  • Florencia Agustina Msc Bonnin

    Laboratory of Infectious Diseases and Molecular Biology, Department of Medicine, Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires, Argentina

    2 shared publications
  • Laura Beatriz Talarico

    Laboratory of Infectious Diseases and Molecular Biology, Department of Medicine, Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires, Argentina

    2 shared publications
  • Analía Toledano

    Laboratory of Infectious Diseases and Molecular Biology, Department of Medicine, Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires 1425, Argentina

    1 shared publication
  • Analía Toledano

    Laboratory of Infectious Diseases and Molecular Biology, Department of Medicine, Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires, Argentina

    1 shared publication
  • Azad Kumar

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

    1 shared publication

Latest Publications

  • Persistence of SARS-CoV-2 S IgG Antibodies in Children Post-COVID-19 and the Association of Antibody Levels with Vaccination Status

    by Eduardo L. López, María S. Tineo, Federico Di Gregorio, María F. Pavan, Florencia A. Bonnin, Lidia E. Torrado, Paola J. Karp, Analía Toledano, Ana Caratozzolo, Sergio I. Nemirovsky, et al.

    Children who contracted COVID-19 develop antibodies targeting the SARS-CoV-2 spike (S) protein which persist for 4 to 12 months following infection. We sought to analyze the antibody response to SARS-CoV-2 one year after COVID-19 in children under 18 years, vaccinated or unvaccinated. Blood samples were collected during the acute phase, the convalescence stage and one-year post-disease. Vaccinated adults who had COVID-19 during the same timeframe were analyzed for comparison. Serum SARS-CoV-2 S IgG was assessed using immunoassay, and neutralizing activity was evaluated using a SARS-CoV-2 S-pseudotyped lentivirus assay. Seventy-five children were enrolled, with a median age of 8 years (IQR 3–12), and 35% were vaccinated. Forty-nine adults were included, with a median age of 34 years (IQR 29–44). Among unvaccinated children, median SARS-CoV-2 S IgG levels one year after COVID-19 tended to decrease 2-fold compared to convalescent levels. SARS-CoV-2 antibodies were notably elevated in children with two or three COVID-19 vaccine doses compared to unvaccinated individuals. Children who received mRNA vaccines exhibited higher SARS-CoV-2 IgG titers (p = 0.0028) and neutralizing antibodies (p = 0.0120) compared to those who received inactivated vaccines. SARS-CoV-2 IgG showed no correlation with the severity of the initial illness or the presence of comorbidities. SARS-CoV-2 IgG did not significantly differ between vaccinated children and adults with the same vaccination status. Among unvaccinated children, convalescent levels of IL-1 β and IL-4 positively correlated with one-year antibody responses. This work highlights the significance of vaccinating children to sustain a lasting humoral immune response against SARS-CoV-2, even after infection.

  • Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants

    by Florencia A. Bonnin, Laura B. Talarico, Fausto M. Ferolla, Patricio L. Acosta, Emily Phung, Azad Kumar, Analía Toledano, Ana Caratozzolo, Pablo Neira, Normando Mascardi, et al.